Attached files
| file | filename |
|---|---|
| EX-23 - EXHIBIT 23 - NOVELION THERAPEUTICS INC. | c97388exv23.htm |
| EX-21 - EXHIBIT 21 - NOVELION THERAPEUTICS INC. | c97388exv21.htm |
| EX-32.1 - EXHIBIT 32.1 - NOVELION THERAPEUTICS INC. | c97388exv32w1.htm |
| EX-31.2 - EXHIBIT 31.2 - NOVELION THERAPEUTICS INC. | c97388exv31w2.htm |
| EX-31.1 - EXHIBIT 31.1 - NOVELION THERAPEUTICS INC. | c97388exv31w1.htm |
| EX-32.2 - EXHIBIT 32.2 - NOVELION THERAPEUTICS INC. | c97388exv32w2.htm |
| 10-K - FORM 10-K - NOVELION THERAPEUTICS INC. | c97388e10vk.htm |
EXHIBIT 11
COMPUTATION OF PER SHARE EARNINGS
Basic net income per common share is computed using the weighted average number of common shares
outstanding during the period. Diluted net income per common share is computed in accordance with
the treasury stock method and the “if converted” method, which uses the weighted average number of
common shares outstanding during the period and also includes the dilutive effect of potentially
issuable common stock from outstanding stock options, warrants, and convertible debt. Common
shares issuable upon exercise of certain options and warrants are not used in the calculation for
the years ended December 31, 2005 to 2009, as the effect would be anti-dilutive.
| Year ended December 31, | ||||||||||||||||||||
| 2009 | 2008 | 2007 | 2006 | 2005 | ||||||||||||||||
| (In thousands of U.S. dollars except per share information) | ||||||||||||||||||||
Net income (loss) from continuing operations |
$ | (36,220 | ) | $ | (9,247 | ) | $ | (125,537 | ) | $ | 39,898 | $ | 62,673 | |||||||
Income (loss) from discontinued operations, net of income tax |
135,654 | 144,138 | 15,540 | (141,503 | ) | (388,084 | ) | |||||||||||||
Net income (loss) available to common shareholders |
$ | 99,434 | $ | 134,891 | $ | (109,997 | ) | $ | (101,605 | ) | $ | (325,412 | ) | |||||||
Basic net income (loss) per common share |
||||||||||||||||||||
Continuing operations |
$ | (0.65 | ) | $ | (0.12 | ) | $ | (1.68 | ) | $ | 0.48 | $ | 0.68 | |||||||
Discontinued operations |
2.41 | 1.93 | 0.21 | (1.68 | ) | (4.19 | ) | |||||||||||||
Net income (loss) |
$ | 1.77 | $ | 1.81 | $ | (1.47 | ) | $ | (1.20 | ) | $ | (3.51 | ) | |||||||
Diluted net income (loss) per common share |
||||||||||||||||||||
Continuing operations |
$ | (0.65 | ) | $ | (0.12 | ) | $ | (1.68 | ) | $ | 0.48 | $ | 0.68 | |||||||
Discontinued operations |
2.41 | 1.93 | 0.21 | (1.68 | ) | (4.19 | ) | |||||||||||||
Net income (loss) |
$ | 1.77 | $ | 1.81 | $ | (1.47 | ) | $ | (1.20 | ) | $ | (3.51 | ) | |||||||
Weighted average number of common shares outstanding
(in thousands) |
56,194 | 74,620 | 74,907 | 84,596 | 92,637 | |||||||||||||||
Diluted weighted average number of common shares outstanding (in
thousands) |
56,194 | 74,620 | 74,907 | 84,596 | 92,637 | |||||||||||||||